Secretomes, unlocking the regenerative powers from healthy human cells
MED’INN’Pharma (MIP) is a pre-clinical stage Biotech company founded in 2017 as a spin-off from the French blood bank establishment (EFS) and the French National Institute of Health (INSERM).
Our mission is to use our platform technology to develop a pipeline of disease modifying therapies derived from the secretomes of human cells. We are committed to develop drug candidates with durable efficacy by targeting the root cause of diseases. Our platform derived therapeutics can be tailored to several indications and delivery methods.
RESOLVIX, the lead candidate issued from our technology plateform, is dedicated to actively resolve, heal and regenerate pathologic inflammation in a wide range of degenerative diseases and conditions and with that intended to positively impacting human health span.
We will change the outlook for diseases by
PROVIDING CURATIVE TREATMENTS
MIP’s technology is based on cutting-edge science driven by the goal of developing bioidentic therapeutics to cure diseases. Our propriatery technology platefrom allow us to transform Human cell secretome into drug products, perfectly balanced set of human molecules able to restore dysregulated biological processes. Our lead candidate RESOLVIX is composed of a set of molecules produced by regenerative human macrophages. RESOLVIX can thus tackle inflammatory and degenerative diseases.